Cagrilintide
Cagrilintide (NN9838)
Long-acting amylin analog by Novo Nordisk. Studied with semaglutide as CagriSema.
Typical vial sizes
Sample reconstitution
5 mg vial · 2 mL bac water · 2.75 mg dose
- Draw volume
- 1.100 mL
- Insulin units
- 110 units
- Concentration
- 2.50 mg/mL
- Doses per vial
- 1.8
From the blog
- Pramlintide (Symlin): The FDA-Approved Amylin Analog Behind Today's Obesity Drugs
Long before cagrilintide and amycretin made "amylin" a headline word in obesity research, one drug quietly proved the biology in humans: pramlintide, marketed as Symlin. It remains the only amylin-based medicine with full FDA approval, and it
- Amycretin: Novo Nordisk's Amylin + GLP-1 Dual Agonist, in Oral and Subcutaneous Forms
Amycretin is one of the more closely watched entries in the next wave of obesity and metabolic drug candidates. It is worth being precise about what it is and where it stands: as of mid-2026, amycretin is an investigational, early-stage molecule
Further reading
- Published research on Cagrilintide (PubMed) →
- Clinical trials for Cagrilintide (ClinicalTrials.gov) →
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.